Follow us on Twitter
twitter icon@FreshPatents


Alcoholic Fatty Liver patents

      

This page is updated frequently with new Alcoholic Fatty Liver-related patent applications.




 Composition for preventing and treating non-alcoholic fatty liver diseases patent thumbnailComposition for preventing and treating non-alcoholic fatty liver diseases
A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake.
Jbk Natural Medicine Institute


 Method and system for treating non-alcoholic fatty liver disease patent thumbnailMethod and system for treating non-alcoholic fatty liver disease
A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.. .

 Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine patent thumbnailTreatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.. .
Hadasit Medical Research Services And Development Ltd.


 Novel composition for nonalcoholic fatty liver disease (nafld) patent thumbnailNovel composition for nonalcoholic fatty liver disease (nafld)
The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited


 Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling patent thumbnailMethods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag


 Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease patent thumbnailCrystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
The present invention relates to the composition comprising crystalline xylose-isomerase and at least one salt of a metal and/or alkaline earth metal for the treatment and prevention of non-alcoholic fatty liver disease and other fructose-related disorders.. .
Sciotec Diagnostic Technologies Gmbh


 Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease patent thumbnailPharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease
The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the gpr119 ligand can be useful to treat non-alcoholic fatty liver..
Snu R&db Foundation


 Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof patent thumbnailBerberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.


 Systems, devices and methods for performing medical procedures in the intestine patent thumbnailSystems, devices and methods for performing medical procedures in the intestine
A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Fractyl Laboratories, Inc.


 Method for assessment of hepatic function and portal blood flow patent thumbnailMethod for assessment of hepatic function and portal blood flow
A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the stat test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate.
The Regents Of The University Of Colorado, A Body Corporate


Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)

The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an nlgn4 gene product in the immune cell population using nlgn4 specific primers or nlgn4 specific probes..
Hadasit Medical Research Services And Development Ltd.

Glucagon and glp-1 co-agonist compounds

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company

Lysosomal acid lipase therapy for nafld and related diseases

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
Children's Hospital Medical Center

Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease

The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (nafld). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (aav) containing the gene encoding sirtuin 1 (sirt1) in the prevention and/or treatment of nafld.
Universitat Autònome De Barcelona

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients.
Neurotronic, Inc.

Differential diagnosis of liver disease

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls.
The Regents Of The University Of California

Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect.
Sancilio & Company, Inc.

Method for treating or preventing nonalcoholic fatty liver disease

A method for treating or preventing non-alcoholic fatty liver disease is disclosed. By promoting the expression of six-transmembrane protein of prostate 2 (stamp2) in liver cells, the method can be useful in improving the abnormalities in lipid metabolism in the liver, and also improving insulin resistance, thereby preventing or treating a non-alcoholic fatty liver disease..
Dong-a University Research Foundation For Industry- Academy Cooperation

Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g.
Virginia Commonwealth University

Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (nash).
Intekrin Therapeutics, Inc.

Prevention and treatment of non-alcoholic fatty liver disease

Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. The methods include administering a therapeutically effective amount of phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones to the subject.
Ohio University

Composition and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Metformin salts to treat type2 diabetes

Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.. .
Jiva Pharma, Inc.

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Diagnosis and treatment of incipient diabetes

A method is described for predicting incipient diabetes, metabolic disorders or the metabolic syndrome by developing a personal temporal phosphatase profile, which is generated by measuring phosphatase concentration in stool at a single time-point or multiple time-points. The phosphatase profile further can be used for diagnosing and determining prognosis of other incipient or overt diseases, such as the metabolic syndrome, coronary heart disease, nonalcoholic fatty liver disease, cancers, other chronic or acute diseases or infectious diseases.

Novel 2,4-dinitrophenol formulations and methods using same

The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (dnp). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof..
Yale University

Compositions and methods for treating intestinal hyperpermeability

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

Biaryl derivatives as gpr120 agonists

The present invention relates to biaryl derivatives of formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of formula 1 according to the present invention promote glp-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation..
Lg Life Sciences Ltd.

A novel composition for nonalcoholic fatty liver disease (nafld)

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited

Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least cone compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)..
The Regents Of The University Of California

Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis

Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (nash) measuring chi3l1 levels. In some embodiments, the methods described herein can distinguish nash from nonalcoholic fatty liver disease.
Yale University

Engineered polypeptides having enhanced duration of action

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.

Drug for treatment of nonalcoholic fatty liver disease

The present invention provides a compound useful in the prevention and treatment of nonalcoholic fatty liver disease. The invention relates to a drug for the prevention and/or treatment of nonalcoholic fatty liver disease, the drug having as an active ingredient (r)-2-[3-[[n-(benzoxazol-2-yl)-n-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of these..
Kowa Company, Ltd.



Alcoholic Fatty Liver topics:
  • Liver Disease
  • Fatty Liver
  • Alcoholic Fatty Liver
  • Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Metabolic Syndrome
  • Dyslipidemia
  • C Syndrome
  • Hepatitis A
  • Liver Fibrosis
  • Lipodystrophy
  • Metabolic Syndrome X
  • Polypeptide
  • Syndrome X
  • Overweight


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Alcoholic Fatty Liver for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alcoholic Fatty Liver with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3105

    file did exist - 3096

    2 - 1 - 51